Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC)
Philippe Merle(Hôpital de la Croix-Rousse), Christian Trépo(Hôtel-Dieu de Lyon), F. Habersetzer, Shahid Ahmed(Emory University), Armand Abergel(Inserm), J. Dufour-Lamartinie, D Costantini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), L. Bonyhay, Julien Taı̈eb(Hôpital Européen Georges-Pompidou)
Cited by 18
Related Papers
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914